EA200401059A1 - Композиции аторвастатина, стабилизированные добавками щелочных металлов - Google Patents
Композиции аторвастатина, стабилизированные добавками щелочных металловInfo
- Publication number
- EA200401059A1 EA200401059A1 EA200401059A EA200401059A EA200401059A1 EA 200401059 A1 EA200401059 A1 EA 200401059A1 EA 200401059 A EA200401059 A EA 200401059A EA 200401059 A EA200401059 A EA 200401059A EA 200401059 A1 EA200401059 A1 EA 200401059A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- atorvastatin
- sodium
- magnesium
- hydroxide
- calcium
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title abstract 5
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title abstract 5
- 229960005370 atorvastatin Drugs 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000000654 additive Substances 0.000 title 1
- 239000002184 metal Substances 0.000 title 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- -1 alkali metal salt Chemical class 0.000 abstract 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 abstract 2
- 229910052783 alkali metal Inorganic materials 0.000 abstract 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 abstract 2
- 229910000397 disodium phosphate Inorganic materials 0.000 abstract 2
- 235000019800 disodium phosphate Nutrition 0.000 abstract 2
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 abstract 1
- 208000034599 Dysbetalipoproteinemia Diseases 0.000 abstract 1
- 208000030673 Homozygous familial hypercholesterolemia Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 201000010252 Hyperlipoproteinemia Type III Diseases 0.000 abstract 1
- 239000004115 Sodium Silicate Substances 0.000 abstract 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 abstract 1
- 206010060751 Type III hyperlipidaemia Diseases 0.000 abstract 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 abstract 1
- 229910052782 aluminium Inorganic materials 0.000 abstract 1
- RJZNFXWQRHAVBP-UHFFFAOYSA-I aluminum;magnesium;pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3] RJZNFXWQRHAVBP-UHFFFAOYSA-I 0.000 abstract 1
- ANBBXQWFNXMHLD-UHFFFAOYSA-N aluminum;sodium;oxygen(2-) Chemical compound [O-2].[O-2].[Na+].[Al+3] ANBBXQWFNXMHLD-UHFFFAOYSA-N 0.000 abstract 1
- 229960001770 atorvastatin calcium Drugs 0.000 abstract 1
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 abstract 1
- 239000000920 calcium hydroxide Substances 0.000 abstract 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 abstract 1
- 239000001095 magnesium carbonate Substances 0.000 abstract 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 abstract 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical class [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 abstract 1
- 239000000391 magnesium silicate Substances 0.000 abstract 1
- 229910052919 magnesium silicate Inorganic materials 0.000 abstract 1
- 235000019792 magnesium silicate Nutrition 0.000 abstract 1
- MZUOYVUQORIPHP-MNSAWQCASA-L magnesium;(3r,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate Chemical compound [Mg+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 MZUOYVUQORIPHP-MNSAWQCASA-L 0.000 abstract 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 abstract 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 abstract 1
- 235000019799 monosodium phosphate Nutrition 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910001388 sodium aluminate Inorganic materials 0.000 abstract 1
- 229910000029 sodium carbonate Inorganic materials 0.000 abstract 1
- 235000017550 sodium carbonate Nutrition 0.000 abstract 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 abstract 1
- 235000011121 sodium hydroxide Nutrition 0.000 abstract 1
- 229910000162 sodium phosphate Inorganic materials 0.000 abstract 1
- 239000001488 sodium phosphate Substances 0.000 abstract 1
- 235000011008 sodium phosphates Nutrition 0.000 abstract 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 abstract 1
- 229910052911 sodium silicate Inorganic materials 0.000 abstract 1
- 235000019794 sodium silicate Nutrition 0.000 abstract 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Фармацевтическая композиция, обладающая улучшенной биодоступностью и биоэквивалентностью, включает частицы аморфного и/или кристаллического аторвастатина, размер которых (d) составляет менее чем 150 мкм и средний размер которых (d) составляет приблизительно от 5 до 50 мкм. Аторвастатин может представлять собой одну или более солей из ряда аторвастатин-кальция, аторвастатин-магния, аторвастатин-алюминия, аторвастатин-железа и аторвастатин-цинка. Композиции аторвастатина могут быть стабилизированы путем смешивания с добавкой соли щелочного металла в концентрации приблизительно от 1,2% до менее чем 5% от массы композиции. Добавка соли щелочного металла может являться одной или более солями из ряда карбоната натрия, бикарбоната натрия, гидроксида натрия, силиката натрия, гидроортофосфата натрия, дигидрофосфата натрия, гидрофосфата натрия, фосфата натрия, алюмината натрия, карбоната кальция, гидроксида кальция, карбоната магния, гидроксида магния, силиката магния, алюмината магния и гидроксида алюминия магния. Композиции аторвастатина можно использовать для лечения медицинских состояний, включающих первичную гиперхолестеринемию, дисбеталипопротеинемию и гомозиготную семейной гиперхолестеринемию.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN112DE2002 | 2002-02-14 | ||
PCT/IB2003/000505 WO2003068191A1 (en) | 2002-02-14 | 2003-02-14 | Formulations of atorvastatin stabilized with alkali metal additions |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200401059A1 true EA200401059A1 (ru) | 2005-02-24 |
Family
ID=27620520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200401059A EA200401059A1 (ru) | 2002-02-14 | 2003-02-14 | Композиции аторвастатина, стабилизированные добавками щелочных металлов |
Country Status (23)
Country | Link |
---|---|
US (1) | US20030175338A1 (ru) |
EP (1) | EP1336405A1 (ru) |
JP (1) | JP2005522444A (ru) |
KR (1) | KR20040101229A (ru) |
CN (1) | CN1642526A (ru) |
AP (1) | AP2004003112A0 (ru) |
AR (1) | AR038839A1 (ru) |
AU (1) | AU2003245736A1 (ru) |
BR (1) | BR0307720A (ru) |
CA (1) | CA2475722A1 (ru) |
CO (1) | CO5600997A2 (ru) |
EA (1) | EA200401059A1 (ru) |
EC (1) | ECSP045235A (ru) |
HR (1) | HRP20040829A2 (ru) |
IL (1) | IL163550A0 (ru) |
IS (1) | IS7404A (ru) |
MX (1) | MXPA04007905A (ru) |
NO (1) | NO20043790L (ru) |
OA (1) | OA12777A (ru) |
PE (1) | PE20030935A1 (ru) |
PL (1) | PL371337A1 (ru) |
WO (1) | WO2003068191A1 (ru) |
ZA (1) | ZA200406970B (ru) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
US7361772B2 (en) * | 2001-08-16 | 2008-04-22 | Biocon Limited | Process for the production of atorvastatin calcium |
HUP0500074A3 (en) | 2002-03-18 | 2005-07-28 | Biocon Ltd Bangalore | Amorphous hmg-coa reductase inhibitors of desired particle size and process for producing them |
US7179942B2 (en) | 2002-07-05 | 2007-02-20 | Bicon Limited | Halo-substituted active methylene compounds |
SI1631533T1 (sl) | 2003-04-22 | 2009-08-31 | Bicon Ltd | Nov postopek za stereoselektivno redukcijo beta - ketoestrov |
US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
SK50462005A3 (sk) * | 2003-08-05 | 2005-09-08 | Zentiva, A. S. | Spôsoby stabilizácie atorvastatínu |
AU2003272080A1 (en) | 2003-09-18 | 2005-04-06 | Biocon Limited | Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate |
CA2573316A1 (en) * | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel fenofibrate formulations and related methods of treatment |
EP1786414A4 (en) * | 2004-08-06 | 2008-04-09 | Transform Pharmaceuticals Inc | NEW PHARMACEUTICAL STATIN COMPOSITIONS AND RELEVANT TREATMENT PROCEDURES |
US20090042979A1 (en) * | 2004-08-06 | 2009-02-12 | Transform Pharmaceuticals Inc. | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment |
WO2006039441A2 (en) * | 2004-09-30 | 2006-04-13 | Dr. Reddy's Laboratories Ltd. | Amorphous atorvastatin calcium |
EP1807055A1 (en) * | 2004-10-28 | 2007-07-18 | Warner-Lambert Company LLC | Process for forming amorphous atorvastatin |
AU2005305460B2 (en) * | 2004-11-22 | 2011-04-21 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
JP2008521878A (ja) * | 2004-12-02 | 2008-06-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 非晶質アトルバスタチンの医薬組成物及びその製造のための方法 |
ES2263370B1 (es) * | 2005-02-16 | 2007-12-01 | Ercros Industrial, S.A. | Atorvastatina calcica amorfa estabilizada y procedimiento para su obtencion. |
WO2006123358A2 (en) * | 2005-02-22 | 2006-11-23 | Sun Pharmaceutical Industries Limited | Stabilized atorvastatin-containing formulation |
PT1879862E (pt) * | 2005-05-03 | 2011-04-19 | Ranbaxy Lab Ltd | Sais de magnésio de inibidores de hmg-coa-redutase |
US20070004671A1 (en) * | 2005-05-20 | 2007-01-04 | Agarwal Sudeep K | Stable desloratadine compositions |
WO2007004236A2 (en) * | 2005-07-04 | 2007-01-11 | Ramu Krishnan | Improved drug or pharmaceutical compounds and a preparation thereof |
MX2008001597A (es) * | 2005-08-04 | 2008-04-04 | Transform Pharmaceuticals Inc | Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento. |
AU2006313009B2 (en) * | 2005-11-10 | 2013-10-24 | Alphapharm Pty Ltd | Process to control particle size |
CA2628716C (en) | 2005-11-10 | 2016-09-27 | Alphapharm Pty Ltd | Process to control particle size |
US8084488B2 (en) | 2005-11-21 | 2011-12-27 | Pfizer Inc. | Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium |
WO2007061849A2 (en) * | 2005-11-23 | 2007-05-31 | Merck & Co., Inc. | Method of generating amorphous solid for water-insoluble pharmaceuticals |
US20100168201A1 (en) * | 2005-11-29 | 2010-07-01 | Biocan Limited | Polymorphs of [R-(R*, R*) ]-2-(4-Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid Magnesium Salt (2:1) |
EP1810667A1 (en) * | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
US20070202159A1 (en) * | 2006-02-02 | 2007-08-30 | Mathur Rajeev S | Pharmaceutical composition comprising stabilized statin particles |
US7772273B2 (en) * | 2006-02-10 | 2010-08-10 | Lifecycle Pharma A/S | Stabilized atorvastatin |
WO2007099552A2 (en) * | 2006-03-02 | 2007-09-07 | Matrix Labaratories Ltd | Novel crystalline form of atovastatin hemi-magnesium |
HU227696B1 (en) * | 2006-04-13 | 2011-12-28 | Egyt Gyogyszervegyeszeti Gyar | Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it |
SI22255A (sl) * | 2006-04-14 | 2007-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah |
US20090082421A1 (en) * | 2006-05-11 | 2009-03-26 | Biocon Limited | Crystalline Form B4 of Atorvastatin Magnesium and a Process Thereof |
US20080038332A1 (en) * | 2006-08-10 | 2008-02-14 | Cai Gu Huang | Stable pharmaceutical formulation comprising atorvastatin calcium |
HU227610B1 (en) * | 2006-09-18 | 2011-09-28 | Richter Gedeon Nyrt | Pharmaceutical compositions containing rosuvastatin potassium |
US20100029743A1 (en) * | 2006-09-27 | 2010-02-04 | Dr. Reddy's Laboratories Ltd. | Atorvastatin pharmaceutical compositions |
US20100104636A1 (en) * | 2006-12-21 | 2010-04-29 | Panagiotis Keramidas | Pharmaceutical Compound and Composition |
IS8587A (is) * | 2006-12-27 | 2008-06-28 | Actavis Group Hf. | Atorvastatin lyfjasamsetning |
CN101224205B (zh) * | 2007-01-20 | 2010-11-17 | 石药集团中奇制药技术(石家庄)有限公司 | 一种阿托伐他汀和左旋氨氯地平的组合物及其制备方法 |
IS8607A (is) * | 2007-02-09 | 2008-08-10 | Actavis Group Hf. | Stöðugar atorvastatin samsetningar |
CZ300047B6 (cs) * | 2007-03-02 | 2009-01-21 | Zentiva, A. S. | Farmaceutická kompozice s obsahem úcinné látky atorvastatinu |
WO2008125412A1 (en) * | 2007-04-13 | 2008-10-23 | Nicox S.A. | Crystalline forms of atorvastatin 4-(nitrooxy) butyl ester |
WO2009013633A2 (en) * | 2007-07-20 | 2009-01-29 | Actavis Group Ptc Ehf | Amorphous coprecipitates of atorvastatin pharmaceutically acceptable salts |
WO2009024889A2 (en) | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
WO2009140341A2 (en) * | 2008-05-13 | 2009-11-19 | Dr. Reddy's Laboratories Ltd. | Atorvastatin compositions |
US20110082071A1 (en) * | 2008-05-15 | 2011-04-07 | Amal Elabbadi | Delivery system for an active ingredient |
EP2127628A1 (en) | 2008-05-27 | 2009-12-02 | Ranbaxy Laboratories Limited | Unit dose pack |
EP2318350A4 (en) * | 2008-07-25 | 2012-11-28 | Alphapharm Pty Ltd | ATOVAQUONE WITH PARTICLE DIAMETER (D90) VARIANT FROM MORE THAN 3 muM TO ABOUT 10 muM |
EP2341773A4 (en) * | 2008-09-24 | 2012-03-07 | Merck Sharp & Dohme | PHARMACEUTICAL COMPOSITIONS FROM ATORVASTATIN |
WO2010038688A1 (ja) * | 2008-09-30 | 2010-04-08 | アステラス製薬株式会社 | アトルバスタチン経口投与用粒子状医薬組成物 |
CN101791297B (zh) * | 2010-02-10 | 2012-03-28 | 中国药科大学 | 阿托伐他汀钙口崩片及其制备方法 |
JP5614445B2 (ja) * | 2010-03-29 | 2014-10-29 | アステラス製薬株式会社 | 経口投与用粒子状医薬組成物 |
JP5534004B2 (ja) * | 2010-03-29 | 2014-06-25 | アステラス製薬株式会社 | 口腔内崩壊錠 |
US8372877B2 (en) * | 2010-04-16 | 2013-02-12 | Cumberland Pharmaceuticals | Stabilized statin formulations |
WO2011139256A2 (en) * | 2010-05-04 | 2011-11-10 | Bilgic Mahmut | Stable rosuvastatin formulations |
HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
WO2011154009A1 (en) * | 2010-06-10 | 2011-12-15 | Lifecycle Pharma A/S | Composition comprising an active principle in an amorphous form and a porous adsorbent material |
US20120165386A1 (en) * | 2010-12-27 | 2012-06-28 | Ranbaxy Laboratories Limited | Stable oral pharmaceutial composition of atorvastatin |
IN2014CN04119A (ru) | 2011-11-15 | 2015-07-10 | Reddys Lab Ltd Dr | |
CN104069502B (zh) * | 2013-03-29 | 2018-02-16 | 北京罗诺强施医药技术研发中心有限公司 | 复合骨架材料及其药物组合物 |
JP6507808B2 (ja) * | 2015-04-09 | 2019-05-08 | ニプロ株式会社 | 口腔内崩壊錠 |
WO2017106130A1 (en) | 2015-12-16 | 2017-06-22 | Merck Sharp & Dohme Corp. | Process for preparing pharmaceutical compositions |
EP3184103A1 (en) | 2015-12-21 | 2017-06-28 | Hexal AG | Pharmaceutical composition comprising atorvastatin or a salt thereof |
CN106420645A (zh) * | 2016-11-24 | 2017-02-22 | 浙江新东港药业股份有限公司 | 一种含阿托伐他汀钙片及制备方法 |
CN108421045B (zh) * | 2018-04-02 | 2021-09-24 | 北京海晶生物医药科技有限公司 | 一种阿托伐他汀钙组合物、制剂及其制备方法 |
CN109044989A (zh) * | 2018-10-09 | 2018-12-21 | 河南师范大学 | 一种阿托伐他汀钙胶囊制剂及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
DE69324504T2 (de) * | 1993-01-19 | 1999-08-26 | Warner Lambert Co | Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren |
SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
-
2003
- 2003-02-14 AU AU2003245736A patent/AU2003245736A1/en not_active Abandoned
- 2003-02-14 CA CA002475722A patent/CA2475722A1/en not_active Abandoned
- 2003-02-14 EA EA200401059A patent/EA200401059A1/ru unknown
- 2003-02-14 PE PE2003000161A patent/PE20030935A1/es not_active Application Discontinuation
- 2003-02-14 IL IL16355003A patent/IL163550A0/xx unknown
- 2003-02-14 KR KR10-2004-7012657A patent/KR20040101229A/ko not_active Application Discontinuation
- 2003-02-14 CN CNA038070286A patent/CN1642526A/zh active Pending
- 2003-02-14 OA OA1200400219A patent/OA12777A/en unknown
- 2003-02-14 PL PL03371337A patent/PL371337A1/xx not_active Application Discontinuation
- 2003-02-14 BR BR0307720-9A patent/BR0307720A/pt not_active IP Right Cessation
- 2003-02-14 EP EP03405088A patent/EP1336405A1/en not_active Withdrawn
- 2003-02-14 AR ARP030100494A patent/AR038839A1/es not_active Application Discontinuation
- 2003-02-14 MX MXPA04007905A patent/MXPA04007905A/es not_active Application Discontinuation
- 2003-02-14 JP JP2003567375A patent/JP2005522444A/ja active Pending
- 2003-02-14 WO PCT/IB2003/000505 patent/WO2003068191A1/en active Application Filing
- 2003-02-14 US US10/367,552 patent/US20030175338A1/en not_active Abandoned
- 2003-02-14 AP APAP/P/2004/003112A patent/AP2004003112A0/en unknown
-
2004
- 2004-08-13 IS IS7404A patent/IS7404A/is unknown
- 2004-08-13 CO CO04079402A patent/CO5600997A2/es not_active Application Discontinuation
- 2004-08-16 EC EC2004005235A patent/ECSP045235A/es unknown
- 2004-09-01 ZA ZA200406970A patent/ZA200406970B/en unknown
- 2004-09-09 NO NO20043790A patent/NO20043790L/no unknown
- 2004-09-13 HR HR20040829A patent/HRP20040829A2/xx not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20043790L (no) | 2004-11-08 |
BR0307720A (pt) | 2005-01-25 |
HRP20040829A2 (en) | 2006-07-31 |
ZA200406970B (en) | 2005-06-20 |
AP2004003112A0 (en) | 2004-09-30 |
JP2005522444A (ja) | 2005-07-28 |
MXPA04007905A (es) | 2004-11-26 |
US20030175338A1 (en) | 2003-09-18 |
CN1642526A (zh) | 2005-07-20 |
CA2475722A1 (en) | 2003-08-21 |
PL371337A1 (en) | 2005-06-13 |
EP1336405A1 (en) | 2003-08-20 |
AR038839A1 (es) | 2005-01-26 |
OA12777A (en) | 2006-07-06 |
AU2003245736A1 (en) | 2003-09-04 |
CO5600997A2 (es) | 2006-01-31 |
PE20030935A1 (es) | 2003-10-30 |
ECSP045235A (es) | 2004-09-28 |
WO2003068191A1 (en) | 2003-08-21 |
KR20040101229A (ko) | 2004-12-02 |
IL163550A0 (en) | 2005-12-18 |
IS7404A (is) | 2004-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200401059A1 (ru) | Композиции аторвастатина, стабилизированные добавками щелочных металлов | |
RU2002122752A (ru) | Фармацевтические композиции, содержащие ингибитор а hmg coa редуктазы | |
JP2005522444A5 (ru) | ||
CA2085037A1 (en) | Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor compound | |
MX9400281A (es) | Formulacion de ci-981 oral estable y proceso para prepararla. | |
WO2002071827A3 (en) | Retinoid x receptor modulators | |
GB9900339D0 (en) | Chemical compounds | |
RS55021B1 (sr) | Atorvastatin kalcijum u farmaceutskom obliku, njegovoj smeši i farmaceutskoj formulaciji, koja sadrži atorvastatin kalcijum | |
ES2173172T3 (es) | Derivados de 1,3-dihidroindol-2-ona sustituidos en 3 por un grupo nitrogenado como agonistas y/o antagonistas de la vasopresina y/o de la octocina. | |
YU52502A (sh) | Spravljanje ubrzivača za beton | |
RU2007119641A (ru) | Композиция, включающая ацетаминофен, кофеин и необязательно аспирин в смеси со щелочным агентом для увеличения абсорбции | |
BR9803696A (pt) | Compostos de triazinilaminoestilbeno. | |
PL370495A1 (en) | Method of manufacturing an amorphous form of the hemi-calcium salt of (3r, 5r) 7-[3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl]-3, 5-dihydroxyheptanoic acid (atorvastatin) | |
DK1421944T3 (da) | Antacid- og laksativtablet | |
MXPA02003916A (es) | Composiciones antivirales para papel tisu. | |
CA2322111A1 (en) | Stable, high available halogen 1,3,5-triazine-2,4,6-trione compositions having rapid dissolution rates | |
UA83012C2 (ru) | Кристаллическая форма натриевой соли 3-пиридил-1-гидроксиэтилиден-1,1-бисфосфоновой кислоты | |
CR7419A (es) | Formulacion de atorvastatina estabilizada con aditamentos de metales alcalinos | |
NZ333206A (en) | Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor | |
RU2003117751A (ru) | Жидкие антацидные композиции | |
BR0301725A (pt) | Composições detergentes e métodos para a preparação de grânulos de silicato de metal alcalino | |
KR970059166A (ko) | 새로운 피리돈 카르복실산 화합물을 함유하는 과립형 캡슐제 | |
RU96117952A (ru) | Таблетка с анальгетической и антиревматической активностью | |
JPS649928A (en) | Bathing composition | |
HUT68015A (en) | New compound leustroducsin h, its preparation and pharmaceutical compositions containing them |